CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Berubicin is an anthracycline that has demonstrated significant potential to effectively cross the blood-brain barrier and target central nervous system malignancies. The company’s Phase 2 trial will recruit 243 patients for side-by-side, real-time analysis of Berubicin’s performance against lomustine, the chemotherapy standard of care drug. “We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” CMO Dr. Sandra Silberman said during the webinar.
To view the full article, visit https://ibn.fm/jqKgo
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork